Clinical Trial Update: The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety and efficacy of zanubrutinib in refractory/relapsed autoimmune hemolytic anemia is ongoing, with status currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Refractory/Relapsed Autoimmune Hemolytic Anemia | Phase 2 | Status: UNKNOWN